USFDA approves Roche’s lymphoma therapy
The drug, known chemically as mosunetuzumab, can be administered at a hospital’s outpatient centre, unlike some other follicular…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
mosunetuzumab
CHMP recommends EU conditional approval of Roche’s antibody Mosunetuzumab for people with relapsed…
If approved, Mosunetuzumab would be the first CD20xCD3 T-cell engaging bispecific antibody available to treat Follicular Lymphoma…
Bispecific antibodies will mature after 2021, $6bn estimated sales in oncology by 2025: GlobalData
There are106 bispecific antibody molecules in the pipeline and 263 ongoing/planning to enrol clinical trials involving a…